EIK-1001
- Generic Name
- EIK-1001
Safety and Efficacy of EIK1001-006 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
Phase 2
Recruiting
- Conditions
- Advanced Melanoma
- Interventions
- First Posted Date
- 2024-11-20
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Eikon Therapeutics
- Target Recruit Count
- 740
- Registration Number
- NCT06697301
- Locations
- 🇺🇸
The Oncology Institution of Hope and Innovation, Los Angeles, California, United States
🇺🇸Bioresearch Partner, Hialeah, Florida, United States
🇦🇺Cancer Care Wollongong, Wollongong, New South Wales, Australia
A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC
Phase 2
Recruiting
- Conditions
- NSCLC
- Interventions
- First Posted Date
- 2024-02-07
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- Eikon Therapeutics
- Target Recruit Count
- 70
- Registration Number
- NCT06246110
- Locations
- 🇺🇸
Bioresearch Partner, Hialeah, Florida, United States
🇺🇸University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Providence St Joseph Hospital, Center for Cancer Prevention and Treatment, Orange, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath